Glioblastoma: 2 proteins may drive growth and recurrence of this brain cancer
New targets for glioblastoma, which are believed to drive the grow and recurrence of this brain tumor, have been identified.
A glioblastoma (GBM) tumor contains a complex combination of different cell types, including 'stem-like' cells that are able to initiate brain tumor growth, even when present in very small numbers. These cells, known as brain-tumor initiating cells (BTICs), are believed to be among the cells that can re-initiate GBM if they are not completely eradicated through surgery, radiation and chemotherapy. Thus, BTICs represent an important therapeutic target for GBM treatment strategies.
"We wanted to find out how GBM-derived BTICs are able to initiate a tumor with the ultimate goal of preventing the re-growth of this deadly form of brain cancer," says Dr. Stefano Stifani, neuroscientist at The Neuro and senior investigator on the paper. "What we found is that by impairing the activity of two transcription factors (proteins that control gene expression), termed FOXG1 and TLE, we can significantly reduce the ability of BTICs to give rise to brain tumors." The researchers studied brain tumor growth in an in vivo mouse model using human GBM-derived BTICs. This approach provides what is called an in vivo environment that closely resembles the original human brain tumors. The demonstration that the FOXG1 and TLE proteins are important for the tumor-forming ability of human GBM-derived BTICs has long-term implications because FOXG1 and TLE control the expression of numerous genes. Identifying the genes whose expression is controlled by FOXG1 and TLE is expected to provide further information on the mechanisms involved in GBM tumorigenesis. In the long term, researchers hope to identify multiple important regulators, in order to find new potential therapeutic targets to impair the tumorigenic ability of BTICs.
"The implication of transcription factors FOXG1 and TLE in the tumor-forming ability of BTICs opens the door to possible strategies to block tumor growth -- a major advance in the fight against GBM."
Source: Science Daily: http://www.sciencedaily.com/releases/2014/01/140108123719.htm